Why Are Companion Diagnostics So Important?

Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?

Jun 30, 2014 at 1:00PM

Over the last year, biotech investors have been consumed by excitement surrounding a new class of cancer drugs that uses the body's own defenses to battle tumors. Unlike the poisonous chemotherapies of the past, these cancer smart bombs, known as immunotherapies, prompt the immune system to attack only cancer cells based on their unique molecular signatures. For these therapies to work we'll need an in-depth understanding of the chemistry of a cancer cell and how it can differ between patients that seem to have the same disease. Once we do, these biomarkers will be used to develop personalized treatment plans for every cancer patient.

As the 2014 ASCO conference has come and gone, it has become only more clear that while patients may appear to share disease symptoms, their treatment options will be greatly dictated by the chemistry of their disease. The much-discussed PD-1 and PDL-1 inhibitors provide a great example. Some tumors express the PDL-1 marker, which cloaks the tumor from immune attack. PD-1 and PDL-1 inhibitors remove the cloak to promote an immune response, but should theoretically work best in patients with higher PDL-1 expression.

At ASCO, Bristol-Myers Squibb (NYSE:BMY) presented data from a Phase 1b trial testing its PD-1 inhibitor, nivolumab, as a monotherapy in patients with non-small cell lung cancer, or NSCLC. Those data, displayed in the table below, show how critical PDL-1 expression is for efficacy.

 # of PatientsOverall Response Rate
PDL-1 pos 10 50%
PDL-1 neg 7 0%
PDL-1 unavailable 3 33%
Total 20 30%

The trial is undoubtedly small and was designed primarily to measure safety, but these results are suggestive enough that Bristol-Myers and other immuno-oncology players have begun more robust late stage trials that focus on PDL-1 positive patients.

Why invest in companion diagnostics?
It's natural to ask if there's an investment opportunity wrapped up in the growing demand for companion diagnostics as immuno-oncology evolves. While the science may seem complex, many of the diagnostic techniques with potential for the clinic are already being employed in basic research labs throughout academia. So while the federal sequester and NIH budget questions have limited growth for life science tools providers in the academic sector, the clinical sector remains a growing and lucrative market.

That's been the case for Qiagen (NASDAQ:QGEN), the maker of basic laboratory kits and supplies ubiquitous in biology labs across the country. In 2013, as the NIH was tightening its belt, Qiagen saw revenue from academic customers drop 2% YoY, while revenue in its molecular diagnostics segment grew 7% and now represents 50% of Qiagen's sales.

Qiagen's diagnostic offerings center around its QIAsymphony family of automated sample preparation and analysis equipment. Diagnostic kits-such as the recently FDA approved therascreen KRAS RGQ PCR kit paired with Amgen's Vectibix-serve as a recurring revenue stream compatible with the QIAsymphony device, effectively anchoring Qiagen's role in diagnostic medicine. With three companion diagnostics approved in the US and a handful more in Europe and Asia Qiagen is actively expanding its menu of tests, making QIAsymphony a more and more relevant device with each new approval. The company's bottom line has been crippled by restructuring and other administrative expenses, but its solid 22% free cash flow growth tells a different story, and suggests that the transition to a diagnostic-focused business is paying off.

Recognition of the growth opportunities in cancer diagnostics also fueled Agilent Technologies' (NYSE:A) 2012 acquisition of Dako, the maker of diagnostic equipment, antibodies, and kits, with a particular focus in oncology. Diagnostics only contributed 7% of Agilent's revenue in the most recent quarter, but at 7% growth it represents the second fastest growing segment of the company's nine end markets. Its pipeline continues to show promise, supplementing partnerships with Bristol-Myers, Pfizer, AstraZeneca, Amgen, and Eli Lilly with a newly announce collaboration with Merck. That will have Agilent's diagnostic paired with what many consider to be the leading PD-1 inhibitor in a market where molecular diagnostics will be in high demand. When Agilent spins off its slower growing electronics segment in November, a streamlined focus on life sciences and diagnostics could help it harness that growth potential.

Illumina will also be worth a look for those intrigued by the prospects of companion diagnostics. Best known for breaking the $1,000 per genome sequence barrier, Illumina also makes smaller bench-top sequencing devices for research and clinical settings with its MiSeqDx next generation sequencing device. In November, the FDA approved Illumina's cystic fibrosis test as the first clinically available next generation sequencing diagnostic tool. Now at the forefront of genetics technology and with an approved platform under its belt, Illumina is sure to be a major player in both diagnostics and research-focused sequencing.

Bottom line
While developments in oncology are unlocking brilliant new approaches to treating cancer, new therapies will actually be applicable to fewer patients. Targeted therapies will enable clinicians to pinpoint tumors and spare healthy tissue, but will require new diagnostic tools to inform personalized treatment options. Companion diagnostics that are marketed along side new drugs present a growing industry that will continue to expand with immuno-oncology.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Seth Robey owns shares of Amgen. The Motley Fool recommends Illumina and Qiagen. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers